- Home
- HHS vs GDTC Comparison
HHS vs GDTC Comparison
Compare HHS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- GDTC
- Stock Information
- Founded
- HHS 1923
- GDTC 2018
- Country
- HHS United States
- GDTC Singapore
- Employees
- HHS N/A
- GDTC N/A
- Industry
- HHS Advertising
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- GDTC Health Care
- Exchange
- HHS Nasdaq
- GDTC Nasdaq
- Market Cap
- HHS 30.3M
- GDTC 28.0M
- IPO Year
- HHS N/A
- GDTC 2023
- Fundamental
- Price
- HHS $3.75
- GDTC $2.31
- Analyst Decision
- HHS
- GDTC Buy
- Analyst Count
- HHS 0
- GDTC 1
- Target Price
- HHS N/A
- GDTC $5.00
- AVG Volume (30 Days)
- HHS 31.5K
- GDTC 5.7K
- Earning Date
- HHS 08-07-2025
- GDTC 01-01-0001
- Dividend Yield
- HHS N/A
- GDTC N/A
- EPS Growth
- HHS N/A
- GDTC N/A
- EPS
- HHS N/A
- GDTC N/A
- Revenue
- HHS $181,355,000.00
- GDTC $368,838.00
- Revenue This Year
- HHS $6.54
- GDTC $5.37
- Revenue Next Year
- HHS N/A
- GDTC N/A
- P/E Ratio
- HHS N/A
- GDTC N/A
- Revenue Growth
- HHS N/A
- GDTC N/A
- 52 Week Low
- HHS $3.24
- GDTC $1.20
- 52 Week High
- HHS $8.85
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- HHS 40.02
- GDTC 55.02
- Support Level
- HHS $3.24
- GDTC $2.08
- Resistance Level
- HHS $4.35
- GDTC $2.34
- Average True Range (ATR)
- HHS 0.54
- GDTC 0.10
- MACD
- HHS 0.00
- GDTC 0.00
- Stochastic Oscillator
- HHS 23.72
- GDTC 85.71
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.